Swine Erysipelas in Pigs: Pathogen, Symptoms, and Control

Introduction

Swine erysipelas is a globally distributed bacterial disease of pigs caused by the Gram-positive rod Erysipelothrix rhusiopathiae. The disease manifests in acute, subacute, and chronic forms, with the acute presentation characterized by septicemia and characteristic diamond-shaped skin lesions. Chronic infection frequently leads to vegetative valvular endocarditis and non-suppurative polyarthritis, causing significant economic losses in swine production systems. This article provides a detailed review of the pathogen, clinical signs, diagnostic approaches, vaccination strategies, and antimicrobial treatment protocols for swine erysipelas.

Pathogen: Erysipelothrix rhusiopathiae

Taxonomy and Morphology

Erysipelothrix rhusiopathiae is a facultatively anaerobic, non-spore-forming, non-acid-fast, Gram-positive bacillus. The organism exhibits a pleomorphic morphology, appearing as straight or slightly curved rods that can form long filaments in older cultures. The bacterium is classified within the family Erysipelotrichaceae, order Erysipelotrichales, class Erysipelotrichia, phylum Firmicutes.

Biochemical Characteristics

The organism produces hydrogen sulfide (H2S) on triple sugar iron (TSI) agar, a key biochemical feature used for differentiation from morphologically similar organisms such as Arcanobacterium pyogenes and Listeria monocytogenes. E. rhusiopathiae is catalase-negative, oxidase-negative, and produces acid from glucose, lactose, and fructose but not from mannitol or xylose. The bacterium hydrolyzes esculin and produces a characteristic alpha-hemolysis on blood agar.

Serotypes and Antigenic Structure

At least 28 serotypes (serovars 1a, 1b, 2 through 23, and type N) have been identified based on heat-stable peptidoglycan antigens. Serotypes 1a, 1b, and 2 are most commonly associated with clinical disease in swine. The protective antigen is a surface protein known as SpaA (surface protective antigen A), which is a target for vaccine development and serological assays.

Environmental Persistence

E. rhusiopathiae is remarkably resilient in the environment. The bacterium can survive for months in soil, feces, and carcasses. It persists in salted, smoked, and pickled meat products, which has implications for zoonotic transmission (erysipeloid in humans). The organism is susceptible to common disinfectants including sodium hypochlorite, quaternary ammonium compounds, and glutaraldehyde, but it is resistant to desiccation and freezing.

Virulence Factors

Key virulence determinants include:

• SpaA (Surface Protective Antigen A): A surface-anchored protein that mediates adhesion to host endothelial cells and is essential for virulence. SpaA elicits a protective immune response.
• Neuraminidase: An enzyme that cleaves sialic acid residues from host cell surfaces, facilitating bacterial adherence and invasion.
• Hyaluronidase: Degrades hyaluronic acid in connective tissue, promoting bacterial dissemination.
• Hemolysins: Cytolytic toxins that damage host cell membranes, contributing to tissue necrosis and septicemia.

Epidemiology

Host Range and Transmission

Swine are the primary reservoir, but E. rhusiopathiae infects a wide range of mammals and birds, including turkeys, sheep, cattle, and marine mammals. Transmission occurs via the fecal-oral route through ingestion of contaminated feed, water, or soil. The bacterium can also enter through skin abrasions. Carrier pigs shed the organism intermittently in feces, urine, and oronasal secretions. Stress factors such as overcrowding, poor ventilation, sudden feed changes, and concurrent infections precipitate clinical outbreaks.

Risk Factors

• Age: Grower-finisher pigs (8 to 20 weeks of age) are most susceptible.
• Housing: Intensive confinement systems with poor hygiene increase transmission risk.
• Season: Outbreaks are more common in warmer months, possibly due to increased environmental survival.
• Immune Status: Naive herds with no prior exposure or vaccination history are highly susceptible.

Clinical Signs

Acute Form

The acute form is characterized by sudden onset of septicemia. Clinical signs include:

• Fever: Rectal temperatures of 40.5 to 42.0 degrees Celsius.
• Depression and Anorexia: Affected pigs are lethargic and refuse feed.
• Diamond-Shaped Skin Lesions: Pathognomonic urticarial plaques that are raised, erythematous, and rhomboid in shape. These lesions appear 24 to 48 hours after fever onset and may coalesce into large areas of necrosis.
• Mortality: Death can occur within 2 to 4 days in peracute cases. Mortality rates range from 5% to 25% in untreated outbreaks.

Subacute Form

Subacute disease presents with milder fever, transient skin lesions, and reduced appetite. Recovery is common within 7 to 10 days, but chronic sequelae may develop.

Chronic Form

Chronic infection develops weeks to months after acute disease or may occur without a recognized acute phase. Two primary manifestations exist:

• Vegetative Valvular Endocarditis: Bacterial colonization of heart valves, most commonly the mitral valve, leads to proliferative, cauliflower-like vegetations. Clinical signs include exercise intolerance, cyanosis, dyspnea, and sudden death. Auscultation reveals a loud, harsh systolic murmur.
• Non-Suppurative Polyarthritis: Immune-mediated inflammation of joints, particularly the carpal, tarsal, and stifle joints. Affected pigs exhibit lameness, joint swelling, and reluctance to move. Joint fluid is serosanguinous with increased neutrophil counts.

Diagnosis

Clinical Diagnosis

Presumptive diagnosis is based on the presence of characteristic diamond-shaped skin lesions in febrile pigs. However, differential diagnoses include porcine dermatitis and nephropathy syndrome (PDNS), classical swine fever, and sunburn.

Laboratory Diagnosis

Bacteriological Culture

E. rhusiopathiae can be isolated from blood, skin lesions, joint fluid, heart valves, and internal organs (spleen, liver, kidney). Samples are cultured on blood agar or selective media containing sodium azide and crystal violet. Colonies appear as small, transparent, alpha-hemolytic after 24 to 48 hours of incubation at 37 degrees Celsius under microaerophilic conditions.

Polymerase Chain Reaction (PCR)

PCR assays targeting the SpaA gene or 16S rRNA gene provide rapid and specific detection. Real-time PCR (qPCR) offers quantitative results and is particularly useful for detecting carrier animals and environmental samples. PCR can be performed on fresh tissue, formalin-fixed paraffin-embedded tissue, and joint fluid.

Serology

Serological tests detect antibodies against E. rhusiopathiae. The most common methods are:

• Enzyme-Linked Immunosorbent Assay (ELISA): Commercial ELISA kits detect antibodies against SpaA. Serology is useful for herd-level surveillance and vaccine response monitoring but has limited utility for individual diagnosis due to the prevalence of subclinical infection and vaccination.
• Agglutination Tests: Tube agglutination and microagglutination tests measure antibody titers. A four-fold rise in titer between acute and convalescent sera supports a diagnosis of active infection.

Histopathology

Histological examination of skin lesions reveals acute vasculitis, thrombosis, and necrosis of the epidermis and dermis. Chronic arthritis shows synovial hyperplasia, lymphoplasmacytic infiltration, and pannus formation. Heart valves exhibit fibrinoid necrosis and bacterial colonies embedded in vegetative masses.

Differential Diagnosis

Treatment

Antimicrobial Therapy

E. rhusiopathiae is susceptible to a range of beta-lactam antibiotics. Penicillin G is the drug of choice for acute cases. Recommended treatment protocols include:

• Penicillin G Procaine: 20,000 to 30,000 IU/kg intramuscularly once daily for 3 to 5 days.
• Amoxicillin: 15 mg/kg intramuscularly or orally twice daily for 5 days.
• Ceftiofur: 3 to 5 mg/kg intramuscularly once daily for 3 days.
• Tylosin: 10 mg/kg intramuscularly once daily for 3 days.

In acute outbreaks, mass medication via feed or water is effective. In-feed antibiotics include chlortetracycline (400 to 600 g/ton) or tiamulin (100 to 200 g/ton) administered for 7 to 14 days.

Antimicrobial Resistance

Resistance to tetracyclines and macrolides has been reported, but beta-lactam resistance remains rare. Susceptibility testing by disk diffusion or broth microdilution is recommended for recurrent outbreaks or treatment failures.

Supportive Care

Affected pigs benefit from non-steroidal anti-inflammatory drugs (NSAIDs) such as flunixin meglumine or meloxicam to reduce fever and inflammation. Electrolyte supplementation and good nursing care improve recovery rates.

Vaccination

Vaccine Types

Two main types of vaccines are available:

• Bacterins (Killed Vaccines): Formalin-inactivated whole-cell vaccines adjuvanted with aluminum hydroxide or oil emulsions. These vaccines induce humoral immunity against SpaA and provide protection against clinical disease for 4 to 6 months.
• Modified Live Vaccines (MLV): Attenuated strains of E. rhusiopathiae administered via drinking water or injection. MLVs induce both humoral and cell-mediated immunity and provide longer-lasting protection.

Vaccination Protocols

• Sows: Vaccinate 2 to 4 weeks before farrowing to provide passive immunity to piglets via colostrum.
• Piglets: Vaccinate at 8 to 12 weeks of age, with a booster 3 to 4 weeks later.
• Replacement Gilts: Vaccinate twice before introduction to the breeding herd.

Vaccine Efficacy

Vaccination reduces the incidence of acute disease and chronic sequelae but does not prevent colonization or shedding. Herd immunity is essential for outbreak prevention. Vaccine failures can occur due to improper storage, administration errors, or infection with heterologous serotypes not covered by the vaccine.

Control and Prevention

Biosecurity

• All-In/All-Out Production: Reduces pathogen build-up in facilities.
• Rodent and Bird Control: Rodents and birds can carry E. rhusiopathiae and introduce infection into herds.
• Disinfection: Thorough cleaning and disinfection of pens between groups using sodium hypochlorite or glutaraldehyde.
• Quarantine: New arrivals should be isolated for 30 days and vaccinated before introduction.

Herd Management

• Stress Reduction: Minimize overcrowding, provide adequate ventilation, and maintain stable social groups.
• Nutrition: Ensure balanced rations with adequate vitamins and minerals to support immune function.
• Monitoring: Regular clinical inspection and serological surveillance for early detection of infection.

Eradication

Eradication is difficult due to the environmental persistence of the organism and the existence of carrier pigs. Depopulation and repopulation with specific-pathogen-free (SPF) stock is the most effective but costly approach.

Diagnostic Workflow

The following Mermaid diagram illustrates a diagnostic decision tree for swine erysipelas.

flowchart TD
    A[Clinical Signs: Fever, Diamond Skin Lesions, Lameness], > B{Acute or Chronic?}
    B, >|Acute| C[Blood Culture & PCR]
    B, >|Chronic| D[Joint Fluid Culture & PCR]
    C, > E{Positive?}
    D, > E
    E, >|Yes| F[Confirm E. rhusiopathiae]
    E, >|No| G[Serology: ELISA or Agglutination]
    G, > H{Titer Rise?}
    H, >|Yes| F
    H, >|No| I[Consider Differential Diagnoses]
    F, > J[Antimicrobial Treatment & Vaccination Review]

Conclusion

Swine erysipelas remains a significant cause of morbidity and mortality in pig herds worldwide. The causative agent, Erysipelothrix rhusiopathiae, is a resilient environmental pathogen capable of causing acute septicemia and chronic endocarditis and arthritis. Diagnosis relies on clinical signs, bacterial culture, PCR, and serology. Penicillin remains the first-line treatment, and vaccination is the cornerstone of prevention. Integrated control programs combining biosecurity, stress reduction, and strategic vaccination are essential for minimizing economic losses.

References

1. Opriessnig T, Hoffman LJ, Harris DL, Gaul SB, Halbur PG. Erysipelothrix rhusiopathiae: genetic characterization of Midwest US isolates and live commercial vaccines using pulsed-field gel electrophoresis. Journal of Veterinary Diagnostic Investigation. 2004;16(2):101-107.
2. Wood RL. Erysipelas. In: Straw BE, Zimmerman JJ, D'Allaire S, Taylor DJ, editors. Diseases of Swine. 9th ed. Ames: Blackwell Publishing; 2006. p. 649-662.
3. Bender JS, Shen HG, Irwin CK, Schwartz KJ, Opriessnig T. Characterization of Erysipelothrix species isolates from clinically affected pigs, environmental samples, and vaccine strains from six recent swine erysipelas outbreaks in the United States. Clinical and Vaccine Immunology. 2010;17(10):1605-1611.
4. Wang Q, Chang BJ, Riley TV. Erysipelothrix rhusiopathiae. Veterinary Microbiology. 2010;140(3-4):405-417.
5. To H, Nagai S. Genetic and antigenic diversity of the surface protective antigen (Spa) of Erysipelothrix rhusiopathiae. Clinical and Vaccine Immunology. 2007;14(7):813-820.